{"id":115475,"date":"2025-02-28T15:39:24","date_gmt":"2025-02-28T15:39:24","guid":{"rendered":"https:\/\/peraltafinancing.com\/business\/finance\/generic-drugmaker-amneal-clocks-mixed-q4-earnings-plans-expansion-in-high-growth-areas-like-weight-loss-products-biosimilars-amneal-pharmaceuticals-nasdaqamrx\/"},"modified":"2025-02-28T15:39:24","modified_gmt":"2025-02-28T15:39:24","slug":"generic-drugmaker-amneal-clocks-mixed-q4-earnings-plans-expansion-in-high-growth-areas-like-weight-loss-products-biosimilars-amneal-pharmaceuticals-nasdaqamrx","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=115475","title":{"rendered":"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars – Amneal Pharmaceuticals (NASDAQ:AMRX)"},"content":{"rendered":"


\n
<\/p>\n

\n
\n

On Friday,\u00a0Amneal Pharmaceuticals Inc.<\/strong> AMRX<\/span>\u00a0reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the\u00a0consensus of $0.15<\/a>.<\/p>\n

The company reported sales of $730.52 million, up 18% year-over-year, beating the\u00a0consensus of $707.6 million<\/a>.<\/p>\n

The increase was driven by Affordable Medicines (previously Generics) revenues growing 21% due to new product launches, biosimilars, and multiple other complex products, AvKARE revenues growing 14% due to new product launches, and Specialty revenues growing 16% driven by key branded products including CREXONT.<\/p>\n

Also Read: Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock<\/a><\/strong><\/p>\n

It clocked a net loss of $31 million compared to a net loss of $99 million a year ago. Adjusted EBITDA\u00a0in the fourth quarter of 2024 was $155 million, an increase of 9% compared to the fourth quarter of 2023, primarily due to strong revenue growth partially offset by higher spending in research and development and commercial initiatives to drive future growth.<\/p>\n

Guidance:<\/strong> Amneal expects 2025 revenues of $3 billion\u2014$3.1 billion and adjusted EPS of $0.65-$0.70 versus the consensus of $2.9 billion and $0.71, respectively.<\/p>\n

“In 2025 and beyond, we are entering a new phase of growth by further expanding in high-growth areas such as Specialty, Biosimilars, and GLP-1 therapies. As a growing and diversified biopharmaceutical company, Amneal is well positioned to deliver substantial value creation for all our stakeholders,” said Chirag and Chintu Patel, Co-Chief Executive Officers.<\/p>\n

The company expects 2025 adjusted EBITDA of $650 million\u2014$675 million, operating cash flow\u00a0of $255 million\u2014$285 million and capital expenditures of approximately $100 million.<\/p>\n

Price Action:<\/strong> At the time of this writing, Friday, AMRX stock was up 1.43% at $8.50 during the premarket session.<\/p>\n

Read Next:<\/strong><\/p>\n<\/div>\n

Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n

\u00a9 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"

On Friday,\u00a0Amneal Pharmaceuticals Inc. AMRX\u00a0reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the\u00a0consensus of $0.15. The company reported sales of $730.52 million, up 18% year-over-year, beating the\u00a0consensus of $707.6 million. The increase was driven by Affordable Medicines (previously Generics) revenues growing 21% due to new product launches, […]<\/p>\n","protected":false},"author":1,"featured_media":115478,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[93],"tags":[51302,11482,51303,8276,51301,12829,2165,9935,36317,8681,1972,51304,15827,5770,6089,1337],"dealstore":[],"offerexpiration":[],"class_list":["post-115475","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance","tag-amneal","tag-areas","tag-biosimilars","tag-clocks","tag-drugmaker","tag-earnings","tag-expansion","tag-generic","tag-highgrowth","tag-loss","tag-mixed","tag-nasdaqamrx","tag-pharmaceuticals","tag-plans","tag-products","tag-weight"],"yoast_head":"\nGeneric Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars - Amneal Pharmaceuticals (NASDAQ:AMRX) - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=115475\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars - Amneal Pharmaceuticals (NASDAQ:AMRX) - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"On Friday,\u00a0Amneal Pharmaceuticals Inc. AMRX\u00a0reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the\u00a0consensus of $0.15. The company reported sales of $730.52 million, up 18% year-over-year, beating the\u00a0consensus of $707.6 million. The increase was driven by Affordable Medicines (previously Generics) revenues growing 21% due to new product launches, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=115475\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-28T15:39:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png\" \/>\n\t<meta property=\"og:image:width\" content=\"830\" \/>\n\t<meta property=\"og:image:height\" content=\"553\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=115475#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=115475\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars – Amneal Pharmaceuticals (NASDAQ:AMRX)\",\"datePublished\":\"2025-02-28T15:39:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=115475\"},\"wordCount\":308,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=115475#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png\",\"keywords\":[\"Amneal\",\"Areas\",\"Biosimilars\",\"clocks\",\"Drugmaker\",\"earnings\",\"Expansion\",\"Generic\",\"HighGrowth\",\"Loss\",\"Mixed\",\"NASDAQAMRX\",\"pharmaceuticals\",\"Plans\",\"Products\",\"WEIGHT\"],\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=115475#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=115475\",\"url\":\"https:\/\/fivemor.com\/?p=115475\",\"name\":\"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars - Amneal Pharmaceuticals (NASDAQ:AMRX) - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=115475#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=115475#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png\",\"datePublished\":\"2025-02-28T15:39:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=115475#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=115475\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/?p=115475#primaryimage\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png\",\"width\":830,\"height\":553},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=115475#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars – Amneal Pharmaceuticals (NASDAQ:AMRX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars - Amneal Pharmaceuticals (NASDAQ:AMRX) - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=115475","og_locale":"en_US","og_type":"article","og_title":"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars - Amneal Pharmaceuticals (NASDAQ:AMRX) - Som2ny Network","og_description":"On Friday,\u00a0Amneal Pharmaceuticals Inc. AMRX\u00a0reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the\u00a0consensus of $0.15. The company reported sales of $730.52 million, up 18% year-over-year, beating the\u00a0consensus of $707.6 million. The increase was driven by Affordable Medicines (previously Generics) revenues growing 21% due to new product launches, […]","og_url":"https:\/\/fivemor.com\/?p=115475","og_site_name":"Som2ny Network","article_published_time":"2025-02-28T15:39:24+00:00","og_image":[{"width":830,"height":553,"url":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=115475#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=115475"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars – Amneal Pharmaceuticals (NASDAQ:AMRX)","datePublished":"2025-02-28T15:39:24+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=115475"},"wordCount":308,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"image":{"@id":"https:\/\/fivemor.com\/?p=115475#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png","keywords":["Amneal","Areas","Biosimilars","clocks","Drugmaker","earnings","Expansion","Generic","HighGrowth","Loss","Mixed","NASDAQAMRX","pharmaceuticals","Plans","Products","WEIGHT"],"articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=115475#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=115475","url":"https:\/\/fivemor.com\/?p=115475","name":"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars - Amneal Pharmaceuticals (NASDAQ:AMRX) - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fivemor.com\/?p=115475#primaryimage"},"image":{"@id":"https:\/\/fivemor.com\/?p=115475#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png","datePublished":"2025-02-28T15:39:24+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=115475#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=115475"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/?p=115475#primaryimage","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2025\/02\/AMRX.png","width":830,"height":553},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=115475#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars – Amneal Pharmaceuticals (NASDAQ:AMRX)"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/115475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=115475"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/115475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/media\/115478"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=115475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=115475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=115475"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=115475"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=115475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}